Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca CEO on revenue beat
11:36am, Thursday, 25'th Jul 2024
AstraZeneca CEO Pascal Soriot joins 'Squawk on the Street' to discuss the company's quarterly earnings results, its goal to double sales by 2030, and its Farxiga drug.
AstraZeneca Lifts Guidance as Demand for Cancer Drugs Grows
11:24am, Thursday, 25'th Jul 2024
Aradhana Sarin, Chief Financial Officer, at AstraZeneca, joins Bloomberg Intelligence to discuss company earnings and their 2030 projections. -------- Watch Bloomberg Radio LIVE on YouTube Weekdays 7a
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
10:35am, Thursday, 25'th Jul 2024
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
10:06am, Thursday, 25'th Jul 2024
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
09:01am, Thursday, 25'th Jul 2024
AstraZeneca (AZN) posted better-than-expected results for the second quarter and lifted its full-year guidance Thursday as revenue grew in nearly all of its product categories compared to the same tim
AstraZeneca ups annual guidance as first half half revenues surge
03:30am, Thursday, 25'th Jul 2024
AstraZeneca PLC (LSE:AZN) has raised its guidance for revenue and earnings this year after first-half sales jumped by 18%. Pascal Soriot, chief executive, said: "Building on our strong growth in the
AstraZeneca lifts full-year outlook on upbeat demand for therapies
02:07am, Thursday, 25'th Jul 2024
Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
12:15pm, Tuesday, 23'rd Jul 2024
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
11:50am, Monday, 22'nd Jul 2024
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
AstraZeneca could upgrade expectations after setting out bold growth plans
07:43am, Friday, 19'th Jul 2024
AstraZeneca PLC (LSE:AZN) releases its quarterly results next Thursday in the wake of an Investor Day at which outlined its bold plan to almost double its turnover to $80 billion by the end of the de
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
01:50pm, Thursday, 18'th Jul 2024
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
11:45am, Thursday, 18'th Jul 2024
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
10:56am, Thursday, 18'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
07:21pm, Wednesday, 17'th Jul 2024
In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
10:51am, Tuesday, 16'th Jul 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
